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Abstract
Autologous chondrocyte transplantation (ACT) has been
shown, in long-term follow-up studies, to be a promising
treatment for the repair of isolated cartilage lesions. The method
is based on an implantation of in vitro expanded chondrocytes
originating from a small cartilage biopsy harvested from a non-
weight-bearing area within the joint. In patients with
osteoarthritis (OA), there is a need for the resurfacing of large
areas, which could potentially be made by using a scaffold in
combination with culture-expanded cells. As a first step towards
a cell-based therapy for OA, we therefore investigated the
expansion and redifferentiation potential in vitro of chondrocytes
isolated from patients undergoing total knee replacement. The
results demonstrate that OA chondrocytes have a good
proliferation potential and are able to redifferentiate in a three-
dimensional pellet model. During the redifferentiation, the OA
cells expressed increasing amounts of DNA and proteoglycans,
and at day 14 the cells from all donors contained type II
collagen-rich matrix. The accumulation of proteoglycans was in
comparable amounts to those from ACT donors, whereas total
collagen was significantly lower in all of the redifferentiated OA
chondrocytes. When the OA chondrocytes were loaded into a
scaffold based on hyaluronic acid, they bound to the scaffold
and produced cartilage-specific matrix proteins. Thus,
autologous chondrocytes are a potential source for the
biological treatment of OA patients but the limited collagen
synthesis of the OA chondrocytes needs to be further explained.
Introduction
Adult articular cartilage consists of a delicate system of cells
and matrix proteins, which have the function of creating a vis-
coelastic tissue with high biomechanical stability and low fric-
tion. Even though the cartilage is exposed to continuous
mechanical wear, there is surprisingly low turnover in cells and
extracellular matrix [1], which could be a reason for the inability
of adult articular cartilage to respond to injuries and subse-
quently repair lesions. This low potential of self-repair has led
to the development of several techniques such as mosaic plas-
tic, microfracture, periosteal transplantation and autologous
chondrocyte transplantation (ACT), all seeking to create a
functional and painless repair of articular cartilage defects.
In ACT, culture-expanded chondrocytes are transplanted
under a cover of periosteum [2]; the method was initially aimed
at the treatment of small isolated lesions. However, 10 years
later, the indication has been expanded to include lesions up
to 20 cm2 in size. This first generation of cell-based treatment
has been followed by a second or third generation, consisting
of culture-expanded cells loaded on a membrane or into a bio-
degradable scaffold before implantation [3,4]. One major
advantage in using scaffolds as cell carriers is that the cells
can be positioned in the lesion, thereby ensuring that the cells
become evenly distributed in the defect. Subsequently, the
degradation time of the scaffold needs to be controlled. This
can be made by different combinations of poly-L-lactic acid
and poly-(lactic-co-glycollic acid) [5] or by the esterification of
hyaluronic acid [6,7]. The scaffold made of hyaluronic acid has
additionally been shown to degrade into chondrogenically
active components [8].
3D = three-dimensional; ACT = autologous chondrocyte transplantation; BSA = bovine serum albumin; DMEM = Dulbecco's modified Eagle's 
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Another major advantage of using a scaffold for delivery of the
cells is the potential for treating larger defects. This is espe-
cially interesting for young (under 60 years old) and active
patients with developed osteoarthritis (OA), who at present
lack an appropriate treatment alternative. The aetiology of OA
has been suggested to contain a phenotypic alteration of the
chondrocytes [9] and disturbance in the proteoglycan metab-
olism due to systematic, mechanical or unknown reasons.
Chondrocytes isolated from OA cartilage have been shown to
be more metabolically active than cells isolated from non-OA
regions in the same joint [10], whereas chondrocytes isolated
from less severe grades of OA cartilage synthesize normal
matrix components [11].
When chondrocytes are isolated from their three-dimensional
(3D) environment in the articular cartilage and expanded in
monolayer cultures, the cells dedifferentiate and gradually lose
their specific phenotype [12,13]. We have shown previously
that dedifferentiated cells from ACT patients have the ability to
differentiate into several mesenchymal phenotypes [14] and
that during redifferentiation towards the chondrogenic pheno-
type the cells express genes known to be involved in the
embryonic formation of cartilage [15].
We therefore proposed, as a first step towards cell-based
treatments for OA, that culture-expanded cells from patients
diagnosed for OA have the capacity to proliferate and produce
matrix proteins in the same quantity as ACT chondrocytes
when placed in a differentiation model.
Materials and methods
Cartilage harvest
Cartilage biopsies were harvested with a curved chisel from
macroscopically affected and unaffected surplus cartilage
from seven patients with OA (age 64 to 83 years), with OA
grades 3 to 5 on the Ahlbäck scale [16], undergoing total knee
replacement. The affected side was considered to be the fem-
oral condyle on the concave side of the knee deformity; that is,
the medial condyle in varus deformity and the lateral in valgus
knees. In all patients the hip–knee–ankle angle was deter-
mined from standing whole-leg radiographs (an angle of more
than 180° indicates a valgus knee deformity). The harvested
biopsies were transported to the cell culture laboratory in ster-
ile saline solution (0.9% NaCl; Fresenius Kabi, Uppsala, Swe-
den) supplemented with gentamicin sulphate (50 mg/l; Gibco,
Paisley, Renfrewshire, UK) and amphotericin B (250 µg/ml;
Gibco). Part of the cartilage biopsy was processed for histol-
ogy, blinded and scored by two independent experienced
researchers in accordance with a modified (biopsies without
subchondral bone) Mankin scale [17], with a maximum score
of 13. The rest of the biopsy was used for cell culture as
described below. The donation of surplus cartilage was
approved by the ethical committee at the Medical Faculty at
Gothenburg University.
Cell culture
The chondrocytes were isolated from the surrounding matrix
by mechanical mincing of the tissue with scalpel followed by
enzymatic treatment overnight with collagenase (0.8 mg/ml;
Worthington Biochemical Corp, Lakewood, NJ, USA) in
Ham's F-12 medium (Invitrogen, Lidingö, Sweden), at 37°C in
7% CO2/93% air. The isolated cells were seeded at 104 cells/
cm2 in culture flasks (Costar; Corning Incorporated, Corning,
NY, USA) in DMEM/F12 medium (Invitrogen) supplemented
with L-ascorbic acid (0.025 mg/ml; Apotekets produktionsen-
het, Umeå, Sweden), gentamicin sulphate (50 mg/l; Gibco),
amphotericin B (250 µg/ml) and L-glutamine (2 mM; Gibco)
with the addition of 10% human serum [18]. In brief, the
human serum was collected in transfusion bags (dry pack;
JMS, Singapore) from healthy blood donors. The serum was
left to coagulate overnight at 4 to 8°C, centrifuged, sterile fil-
tered, divided into aliquots and frozen until use. The first
medium change was made on day 6 and thereafter twice a
week. When the cells reached 80% confluence, they were
subcultured and frozen. Thawed cells were subcultured into
new flasks (Costar) at a density of 4 × 103 cells/cm2.
Three-dimensional pellet culture
After passage 1, the cells were cultured in a 3D pellet culture
system as described previously [15,19]. On days 7 and 14,
the pellets were fixed in Histofix™ (Histolab Products AB,
Göteborg, Sweden), dehydrated and embedded in paraffin.
Sections 5 µm thick were cut and placed on microscope
slides (Superfrost Plus; Menzel-Gläser, Braunschweig, Ger-
many), deparaffinized and stained with Alcian blue/van Gieson
or immunohistochemically with anti-type I collagen and anti-
type II collagen antibodies.
Immunohistochemistry of pellets
Deparaffinized sections were digested with hyaluronidase,
8,000 units/ml (Sigma, St Louis, MO) in 0.1 M PBS for 60 min
at 37°C and blocked with 3% BSA (Sigma) in PBS for 5 min.
The primary antibodies (anti-type I and II collagen; ICN Bio-
medicals, Aurora, OH, USA), diluted 1:150 in PBS containing
3% BSA, were incubated with the sections for 1 hour at room
temperature (20–22°C). The secondary antibody, peroxidase-
conjugated goat anti-mouse (1:150; Jackson Immunoresearch
Laboratories, West Grove, PA, USA) were applied to the sec-
tions for 1 hour at room temperature. A substrate kit (Vector
VIP; Vector Laboratories, Burlingame, CA, USA) was used for
visualization and the results were analysed with a Nikon
Optiphot2-pol microscope (Nikon Instruments Inc, Melville,
NY, USA). Goat cartilage and bone explants were used as a
positive control; for a negative control the primary antibodies
were omitted.
Biochemical analysis of pellets
On days 7 and 14, pellets were digested in papain (Sigma)
solution (0.3 mg/ml in 20 mM sodium phosphate buffer, pH
7.4, containing 1 mM EDTA and 2 mM dithiothreitol) for 60Available online http://arthritis-research.com/content/7/3/R560
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min at 60°C. The digested pellets were then mechanically dis-
solved by vortex-mixing and further analysed for DNA, gly-
cosaminoglycan and hydroxyproline content as described
previously [15]. All biochemical analyses was performed on
triplicate pellets.
Cells in scaffold
Culture-expanded cells (passage 2), 106/cm2 or 5.0 × 106/
cm2, were seeded on human serum precoated Hyaff-11 scaf-
folds (thickness 2 mm; Fidia Advanced Biopolymers, Abano
Terme, Italy) in 100 µl in Ham's F12 medium (Invitrogen) sup-
plemented with 20% human serum. After incubation overnight
at 37°C in 7% CO2/93% air, the scaffolds were cultured in
serum-free medium [15] in non-adherent dishes (Falcon four-
well IVF; Becton Dickinson, Le Pont De Claix, France) for 14
days. After fixation, the scaffolds were embedded in paraffin,
sectioned (10 µm thickness), stained with Alcian blue/van
Gieson and analysed immunohistochemically for type II colla-
gen as described above.
Isolation of total RNA
Total RNA was isolated from cells cultured in a monolayer
(passage 1) and from day 7 pellets with the use of an RNeasy
mini kit (Qiagen, Hilden, Germany) in accordance with the
manufacturer's description. Before RNA isolation, the pellets
were collected in a 1.5 ml micro-tube (Sahrstedt, Nümbrecht,
Germany) containing RLT buffer (Qiagen) and disrupted by
sonication. To remove cell debris and cartilage matrix proteins
a QIAshredder column (Qiagen) was used. Contaminating
genomic DNA was removed from the isolated RNA by using a
DNA-free kit (Ambion, Huntingdon, UK) and total RNA content
and purity were determined spectrophotometrically at 260
and 280 nm. In general, A260/A280 ratios of about 2 were con-
sidered to indicate acceptable purity of the samples [20].
Real-time PCR
Expression patterns of four cartilage genes were analysed by
real-time PCR with an ABI PRISM 7000 (Applied Biosystems,
Foster City, CA, USA) sequence detector and software sys-
tem. TaqMan MGB probes (FAM dye-labelled) and primers for
type I collagen (Hs00164004_m1) and type X collagen
(Hs00166657_m1) were ordered from Applied Biosystems
assays-on-demand (20× assay mixes). The gene-specific
primers and probes for type II collagen 5'-TGG TGT CAA
AGG TCA CAG AGG TTAT-3', antisense 5'-GGA ACC ACT
CTC ACC CTT CACA-3', probe 5'-TCC CTT AGC ACC GTC
CAG GCC TG-3', were designed by using Primer Express
Software version 2.0 (Applied Biosystems). All genes were
designed to amplify fragments of 70 to 150 base pairs; as
endogenous control, 18S rRNA labelled with VIC/TAMRA
was used (Applied Biosystems).
Reverse transcription in vitro was performed with 500 ng of
total RNA with the use of random hexamer primers and Taq-
Man Reverse Transcription reagents (Applied Biosystems).
Real-time PCR was performed with 5 µl of diluted (1:10)
cDNA corresponding to 10 ng of RNA, 15 µl of TaqMan Uni-
versal PCR master mixture (Applied Biosystems), 1× assay-
on-demand mixes of primers and TaqMan MGB probes. All
samples were analysed in triplicate and PCR was performed
in optical 96-well microtitre plates (Applied Biosystems). After
an initial denaturation step at 95°C for 10 min, the cDNA prod-
ucts were amplified with 40 PCR cycles consisting of a dena-
turation step at 95°C for 15 s and an extension step at 60°C
for 1 min.
To analyse the real-time PCR data, a standard curve method
was used. The data were analysed with ABI Prism 7000 SDS
software (Applied Biosystems). For each sample, the Ctsample
values were determined as the cycle number at which all sam-
ples were in the exponential phase of amplification. By using
the formulas below, a value (Y) was obtained as a measure of
the gene expression correlated to the standard curve for that
particular gene: X = (Ctsample - Intercept value)/Slope value;
X10 =  Y. The Y  value for each cDNA sample and target
sequence was divided by the Y value from the housekeeping
gene (18S) for that particular sample to derive a ∆Ct value
(PE-ABI; Sequence Detector User Bulletin 2).
Statistical analysis
Biochemical differences between donors and chondrocytes
isolated from affected and unaffected were analysed with a
two-sided Student's t-test (two-sample equal variance). P <
0.05 was considered significant. All analyses were performed
with cell samples from at least three separate donors unless
otherwise indicated; as a comparison, surplus cells from three
or four donors undergoing ACT were used [15].
Results
After histological preparation, four of the seven isolated biop-
sies were evaluated on the Mankin scale for severity of OA
[17]. The score in these samples varied from 1.5 to 11, and in
two of the patients a significant difference was found between
the affected pathological and unaffected non-pathological
side of the joint (Fig. 1). After mechanical and enzymatic isola-
tion of the chondrocytes from the biopsies, no difference could
be observed in the average number of cells per milligram of
cartilage between the affected and unaffected sides (Table 1).
These numbers did not differ from the average number of cells
isolated from ACT patients [21].
In the primary cultures of the isolated chondrocytes from the
unaffected and affected sides, floating matrix fragments were
initially found in the affected cultures. These fragments did not
seem to affect the proliferation ability and disappeared after
the first change of medium. The cells from the unaffected and
affected sides expanded with, on average, 0.21 and 0.22 cell
doublings per day, respectively. After one passage (4.3 cell
doublings) and 3 weeks of culture, 106 primary cells isolated
from a 400 mg biopsy were expanded into 20 million cells.Arthritis Research & Therapy    Vol 7 No 3    Tallheden et al.
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When the expanded cells were cultured in serum-free medium
in a redifferentiation model they formed spherical pellets over-
night. During this shift from two-dimensional culture to 3D cul-
ture, the cells expressed increasing amounts of type II and type
X collagen, whereas the expression of type I collagen was
unchanged or slightly decreased (Fig. 2). No difference in
expression of these typical cartilage genes was observed
between affected, unaffected and ACT donors.
The shift from a proliferative to a matrix-synthesizing state was
also demonstrated by an increase in the size of pellets from
day 1 to day 14. The histological sections of these pellets
showed flattened cells on the surface and round cells in the
centre (Fig. 3). Spindle-shaped cells were found in the central
part of the pellet in some donors, and the frequency of spindle-
shaped cells was greater in samples isolated from biopsies
with high Mankin scores. In the pellets, sulphated proteogly-
cans were detected by Alcian blue/van Gieson staining at
both days 7 and 14 in all donors (Fig. 3). Metachromatic stain-
ing was normally found throughout the whole pellets, but
slightly weaker staining was found in the day 7 pellet from the
sample with the highest Mankin score (data not shown).
The increase in pellet size during the culture period was
accompanied by a significant increase in DNA amounts in all
samples, except from one donor with Mankin score 11 on the
affected side, between days 7 and 14 (data not shown). Dur-
ing the same period there was an increase in proteoglycan
accumulation in each cell in 63% of all samples. At day 14 no
difference could be observed in the amount of proteoglycans
Table 1
Clinical diagnosis and histological scores of the seven donors
No. Cartilage Age (years) Sex Ahlbäck Varus Valgus HKA angle Diagnosis Mankin Cells/mg
1 Affected 73 Male III Yes 175° Prim OA n/a n/a
Unaffected n/a n/a
2 Affected 74 Male IV Yes 174° Prim OA n/a 2,912
Unaffected n/a 2,422
3 Affected 83 Female V Yes 184° Prim OA n/a 2,147
Unaffected n/a 2,917
4 Affected 81 Female II Yes 182° Sec OA 4.5 2,054
Unaffected 5 1,923
5 Affected 74 Male III Yes 176° Prim OA 11* 1,310
Unaffected 5.5 1,938
6 Affected 64 Female IV Yes 167° Prim OA 1.5 3,465
Unaffected 1.5 3,091
7 Affected 81 Female IV Yes 173° Prim OA 9* 2,649
Unaffected 6.5 2,410
An asterisk indicates a significant difference (P < 0.05) between unaffected and affected biopsies. HKA angle, hip–knee–ankle angle; n/a, not 
analysed; OA, osteoarthritis; Prim, primary; Sec, secondary.
Figure 1
Histology of biopsies Histology of biopsies. The figure shows sections stained with Alcian 
blue/van Gieson. The biopsies originate from two representative autolo-
gous chondrocyte transplantation patients (ACT) (a, b) and from the 
unaffected and affected side from two patients with osteoarthritis (OA) 
undergoing total knee replacement (c–f). (c, e) Biopsy from one OA 
donor (female, aged 81 years) with a Mankin score of 1.5 on both 
sides. (d, f) Biopsy from another OA donor (male, aged 74 years) with 
Mankin scores of 5 (d) and 11 (f).Available online http://arthritis-research.com/content/7/3/R560
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per cell in pellets from the unaffected and affected sides (P >
0.05). In a comparison between OA chondrocytes and those
from patients undergoing ACT only one sample, from the
affected side of a female aged 81 years, had a significantly
lower content of proteoglycans (P < 0.05; Fig. 4a).
The ability of the culture-expanded cells to form collagens in
the pellet model was analysed biochemically and by immuno-
reactivity to type I and type II collagen (Fig. 3). The total
amounts of collagen per cell were significantly lower in all OA
samples than in those from ACT patients (Fig. 4b). By immu-
nohistochemistry, type II collagen was detected in all donors
at day 14, on both affected and unaffected sides, without any
correlation with Mankin score. In the immunohistochemical
analysis for type I collagen, both samples from one donor (a
male aged 74 years) with Mankin scores of 6 (unaffected) and
11 (affected), stained positive at days 7 and 14. The other
samples were only weakly positive at day 14.
To test the potential of using Hyaff-11 as a scaffold for the
delivery of chondrocytes, the scaffold was seeded from the
top with two different concentrations of cell suspensions of
OA samples and samples from ACT patients. After the use of
this technique, the chondrocytes could be detected through-
out the whole thickness of the scaffold, but higher concentra-
tions of cells were observed on the side of the scaffold from
which the cells had been seeded (Fig. 5). This cell distribution
was more obvious in the scaffolds seeded with OA chondro-
cytes than in those seeded with ACT chondrocytes.
Attached to the hyaluronic acid, the chondrocytes redifferenti-
ated within the scaffold, as seen by the secretion of proteogly-
cans and the synthesis of type II collagen (Fig. 5). The
expression of cartilage proteins was more obvious on the
surface of the scaffolds seeded with the high cell density than
those seeded with the low cell density, as shown by the
increased intensity in staining with Alcian blue/van Gieson and
in staining for type II collagen (Fig. 5).
Discussion
Chondrocytes isolated from OA cartilage are able to prolifer-
ate in a monolayer and redifferentiate in 3D models, demon-
strating properties similar to those of non-OA chondrocytes
used for ACT. This indicates that culture-expanded autolo-
gous chondrocytes from OA patients could potentially be
used for resurfacing articular cartilage.
In this paper we studied the potential of chondrocytes isolated
from patients with developed OA. During the initial monolayer
culture, chondrocytes are extracted from their normal 3D envi-
ronment and exposed to an artificial environment consisting of
a plastic surface, culture medium and serum. The plastic pro-
vides a substrate for the growth of the anchorage-dependent
cells and the culture medium stabilizes pH and osmolarity and
supplements the cells with trace compounds and energy
sources (pyruvate and glucose). The added serum contains
high levels of growth factors released by cells and platelets
during the coagulation process of whole blood and has the
ability to stimulate cell proliferation [18]. In this artificial envi-
ronment enriched in growth factors the chondrocytes prolifer-
ate, dedifferentiate and lose their phenotype. The ability of
Figure 2
Gene expression of cells cultured in pellets Gene expression of cells cultured in pellets. The graphs show the quan-
titative gene expression of typical cartilage gene expression markers 
(types I, II and X collagen) in the monolayer (ML) and in day 7 pellets. 
Results are means ± SD for separate donors (n = 4) from samples from 
autologous chondrocyte transplantation patients (black bars) and from 
affected (grey bars) and unaffected (white bars) areas.Arthritis Research & Therapy    Vol 7 No 3    Tallheden et al.
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these dedifferentiated cells to redifferentiate into the chondro-
genic phenotype has been proven to be affected by the
growth factors used during expansion [22] and the number of
cell divisions [23].
In ACT treatments, 106  cells/cm2  are implanted into the
defects under a covering of periosteum or type I/III collagen
membrane [24]. If this treatment were to be used for OA
patients, most probably both the femoral condyle and the tibial
plateau would need restoration. This would mean that sur-
faces about at least 25 cm2 in size should be treated. In the
present study we were able to obtain, from a 400 mg cartilage
biopsy taken from OA patients, 20 million cells within 3 weeks
of culture. This means that without exceeding the number of
cell divisions, which could possibly hamper the
redifferentiation potential [25], it would be necessary to har-
vest about 500 mg of cartilage, which correlates to a circular
biopsy 7.2 mm in diameter on the basis of calculations of nor-
mal hyaline cartilage [26]. The data in this study indicate that
the biopsy could be harvested either from a non-weight-bear-
ing area or from the actual affected area during a cleanout pre-
arthroscopic procedure. However, 106  cells/cm2  greatly
exceeds the cell density in adult cartilage, and the number of
cells actually needed for a successful scaffold-assisted carti-
lage repair has not been defined.
It has previously been demonstrated in several studies that
cells isolated from OA cartilage have limited proliferation
capacity [27] and malfunctioning proteoglycan synthesis
[10,11]. It was therefore a great surprise to us that we
observed a proliferation rate similar to that in samples from
patients treated with ACT and no difference in the proteogly-
can secretion in chondrocytes isolated from affected and
unaffected areas. All samples had the further ability to produce
type II collagen in the pellet model. Possible explanations for
this are that during the proliferation phase the cells are
exposed to an environment and to growth factors, which 'revi-
talizes' the cells [10], or simply that there is a positive selection
of potent cells during the monolayer culture.
Although the chondrocytes from OA patients analysed in this
study produced a cartilage-specific matrix, the ability of the
chondrocytes to redifferentiate seemed be different from that
of chondrocytes isolated from ACT donors [15]. Whereas
Figure 3
Histology of pellets Histology of pellets. The figure shows stained sections of pellets from the unaffected and affected side from same OA donors ((a–f) female, age 81 
years and (g–l) male, age 74 years) as shown in Fig. 1. (a, d, g, f) Alcian blue–van Gieson staining indicating the accumulation of proteoglycans. (b, 
e, h, k) Immunohistochemical staining with anti-type II collagen antibody. (c, f, i, l) Immunohistochemical staining with anti-type I collagen antibody. 
Positive staining is indicated by a red colour in the extracellular matrix.Available online http://arthritis-research.com/content/7/3/R560
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ACT chondrocytes, once placed in the 3D serum-free pellet
model, stopped their DNA synthesis and started to differenti-
ate, the OA chondrocytes continued to proliferate up to day
14. The proliferation was accompanied with significantly less
collagen production in all OA chondrocytes than in ACT
chondrocytes (Fig. 4b). A shift from a differentiated phenotype
to a proliferative state has further been suggested as an expla-
nation for the development of OA [9,28] and could possibly be
reflected in the inability to redifferentiate seen in the pellet
model.
Another important issue in cell-based cartilage repair, espe-
cially for large defects, is the positioning of cells in large
defects. This can be done by delivering the cells to the patient
within a vehicle or a scaffold. Within the scaffold, which is pref-
erably biodegradable and has a controlled degradation time,
the cells are able to attach and to start producing cartilage
matrix. In our study we observed that, within the hyaluronic
acid scaffold after 2 weeks of culture in serum-free medium,
the OA chondrocytes formed cartilage matrix proteins. This
result concurs with previous studies with human epiphyseal
chondrocytes and chick embryonic sternal chondrocytes, in
which an increased expression of cartilage typical genes was
observed in cultures with Hyaff-11 (scaffold based on
hyaluronic acid) [29].
The redifferentiation of the dedifferentiated cells was typically
more obvious in the scaffolds seeded with the high density of
cells (25 × 106 cells/cm3), indicating that the cell density is
important for the restoration of the chondrogenic phenotype.
The cell density and redifferentiation could also be important
for matrix production, because in the scaffolds seeded with a
low cell density (5 × 106 cells/cm3) we observed a threefold to
fivefold lower secretion of proteoglycans compared with the
pellet cultures (data not shown). Similar observations have
been presented by Puelacher and colleagues [30], who
showed that at least 20 × 106 cells/cm3 were needed for good
matrix formation within the scaffold.
Further, it is of great importance that the scaffold, when
implanted into the joint, has the ability to integrate with the sur-
rounding cartilage and with the subchondral bone. Integration
with the subchondral bone could possibly be increased by the
induction of subchondral bleeding, for example by microfrac-
ture. However, the importance of an uninjured subchondral
bone plate for the integrity of the articular cartilage and the
ability to withstand mineralization has not been clarified.
The integration could also be altered by the grade of differen-
tiation of the scaffold, as demonstrated in a study made by
Obradovic and colleagues [31]. They showed that the integra-
tion of tissue-engineered cartilage to articular cartilage
explants was better with immature (redifferentiated for 5 days)
than mature (redifferentiated for 5 weeks) cartilaginous
explants. The positive immunostaining of type II collagen seen
in our scaffold seeded with the higher density of cells could
indicate that the cells had redifferentiated too far and that the
implant would therefore be less integrative. In contrast, in the
treatment of large injuries, the scaffold needs to be able to
withstand mechanical load and shear forces from the time of
implantation. These forces can possibly be lowered by align-
ment of the mechanical axis (tibia osteotomy) to reduce the
weight bearing of the implant, but the scaffold will in any case
be subjected to mechanical stress and will have to be able to
withstand this. A possible way of strengthening the scaffold
without redifferentiation would be to distribute the chondro-
cytes more uniformly in the scaffold by improving the seeding
method. Both spinner flask and perfusion culture techniques
have been shown to be superior to static cultures [32].
Figure 4
Biochemical analysis of pellets Biochemical analysis of pellets. Results are shown of the measurement 
of cartilage matrix protein accumulation in day 14 pellets normalized to 
cell number (DNA) in cells from the unaffected (filled bars) and affected 
(open bars) sides of four consecutive donors; the sex and age (in years) 
of the donors are indicated. Glycosaminoglycan (GAG) (a) and hydrox-
yproline (as a measure of total collagen content) (b) are shown as 
amounts per microgram of DNA. Results are means ± SD for three 
identical pellets. The amounts are compared with the mean value for 
four sequential autologous chondrocyte transplantation patients (ACT). 
An asterisk indicates a significant difference (P < 0.05) between ACT 
and osteoarthritis chondrocytes.Arthritis Research & Therapy    Vol 7 No 3    Tallheden et al.
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Another reason that the implant has to withstand mechanical
stress is that systematic redifferentiation signalling, as part of
the disease condition, could be impaired within the OA joint.
Redifferentiation and proteoglycan synthesis could instead be
stimulated by dynamic mechanical compression of the implant.
The mechanical load could possibly be gradually increased to
adapt to the differentiation state of the implant through specif-
ically developed physiotherapy programmes, which will there-
fore probably have an important role in the development of
biological implants for OA.
Conclusion
We demonstrate in this paper that OA chondrocytes have the
ability to proliferate, redifferentiate and secrete cartilage-spe-
cific matrix proteins. We also show that OA chondrocytes
have an inability to shift definitely from a proliferative to a differ-
entiating state. How to change the cells from a proliferative to
a collagen-secreting phenotype needs to be explored further,
especially when considering the importance of collagen in
maintaining the cartilage structure.
We further showed that the OA chondrocytes are able to bind
to a scaffold, but further studies will be needed to establish
how far the cartilage in this scaffold should be differentiated to
be able to integrate with the surrounding cartilage and
subchondral bone and to withstand the mechanical forces
applied within the joint.
The results in this paper give hopes for finding a cell-based
autologous biological treatment for young active patients with
OA, but we have to remember that there is no normal cartilage
in OA and more research must be done before such a treat-
ment can be put into clinical practice.
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Figure 5
Histology of cell-seeded scaffolds Histology of cell-seeded scaffolds. The figure shows scaffolds seeded with chondrocytes from one representative autologous chondrocyte trans-
plantation (ACT) donor (a–c) and one osteoarthritis (OA) donor (unaffected) at two different cell seeding densities, 106 cells/cm2 (d–f) and 5 × 106 
cells/cm2 (g–i). Accumulation of proteoglycans is shown with Alcian blue/van Gieson stain and the presence of type II collagen is indicated by red 
staining within the scaffold. Panels (b), (e) and (h) are higher magnifications of portions of (a), (d) and (g), respectively.Available online http://arthritis-research.com/content/7/3/R560
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